Seeger Weiss urges a full-court review of proposed negotiation class in opioid litigation

Seeger Weiss LLP filed a petition for rehearing en banc on October 8, 2020, seeking a reconsideration of a proposed negotiation class for In re National Prescription Opiate Litigation by the Sixth Circuit of the U.S. Court of Appeals. Coauthored with by co-lead class counsel, Jayne Conroy of Simmons Hanley Conroy LLC, as well as […]

October 9, 2020

Seeger Weiss LLP filed a petition for rehearing en banc on October 8, 2020, seeking a reconsideration of a proposed negotiation class for In re National Prescription Opiate Litigation by the Sixth Circuit of the U.S. Court of Appeals.

Coauthored with by co-lead class counsel, Jayne Conroy of Simmons Hanley Conroy LLC, as well as special counsel and class counsel for the proposed class, the petition describes the recent 2-1 decision striking down the proposed class as an “attempt to rewrite the history” of Rule 23 of the Federal rules of Civil Procedure.

“Given the stakes of the underlying public health crisis — and the broader stakes in ensuring proper interpretation of the rules — this is simply too important a case to allow a bare 2-1 panel majority to control the outcome,” the class wrote.

“The plaintiffs are moving forward with the MDL litigation, preparing for trials and exploring and discussing potential resolutions with various defendants,” Conroy and Seeger told Law360 in a recent article on the petition. “Meanwhile, we are seeking en banc review because the negotiation class approved by the MDL court is an important mechanism that deserves the full consideration of the entire court of appeal.”

Related News

July 28, 2026
Seeger Weiss Named Pharmaceutical Litigation Practice Group of the Year at the National Law Journal’s 2026 Elite Trial Lawyers Awards

Seeger Weiss has been named as Pharmaceutical Litigation Practice Group of the Year at the National Law Journal’s 2026 Elite Trial Lawyers Awards. This honor is reflects to the Seeger Weiss team’s efforts throughout the entire Pharmaceutical Litigation practice area, but specifically the firm’s work on the GLP-1 RA and Depo-Provera litigations. Partner Parvin Aminolroaya […]

Read More
July 28, 2026
Plaintiffs Reach Uncapped Global Settlement With J&J, Company to Pay Minimum of $5.8 Billion to Resolve Talc Litigation After More Than a Decade

The Plaintiffs’ Negotiation Committee in multi-district litigation 2738 (District of New Jersey), with the support and endorsement of the Plaintiffs’ Executive Committee and the Plaintiffs’ Steering Committee, announces today that it has reached a historic uncapped global settlement with J&J, Company to pay a minimum $5.8 billion settlement to resolve all current and pending talcum […]

Read More
June 29, 2026
Seeger Weiss Earns Tier 1 Ranking in the 2026 Legal 500 USA Guide

Seeger Weiss is proud to announce that the firm has been selected for a Tier 1 ranking in the 2026 Legal 500 USA Guide in the Product Liability, Mass Tort and Class Action: Plaintiff category. Founding Partner Christopher Seeger was selected for inclusion in the category’s Hall of Fame in recognition of his continued leadership […]

Read More